Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors?

Annals of Medicine

Volumn 32, Issue 1, 2000, Pages 1-5

  Malik, Rayaz A ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Angiotensin converting enzyme inhibition; Diabetic neuropathy; Microangiopathy

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENDOTHELIN 1; GAMMA LINOLENIC ACID; LISINOPRIL; NICERITROL; NIFEDIPINE; NIMODIPINE; PRAZOSIN; QUINAPRIL; RECOMBINANT GROWTH FACTOR; SALBUTAMOL; STREPTOZOCIN; TRANDOLAPRIL; TROGLITAZONE; ZOPOLRESTAT;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFICACY; EDITORIAL; FOOT AMPUTATION; HEALTH CARE COST; HUMAN; ISCHEMIC HEART DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; VASCULAR DISEASE; WORLD HEALTH ORGANIZATION;

EID: 0033967211     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890008995903     Document Type: Editorial

References (17)

1. Boulton AJM, Malik RA. Diabetic neuropathy. Med Clin North Am 1998; 82: 909-29.
2. Malik RA. Pathology and pathogenesis of diabetic neuropathy. Diabetes Care 1999; 7: 1-8.
3. The effect of intensive diabetes therapy on the development and progression of neuropathy. Diabetes Control and Complications Trial Research Group. Ann Intern Med 1995; 122: 561-8.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
5. Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ III, O'Brien PC. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999; 22: 1479-86.
6. Forrest KYZ, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neoiropathy. Diabetes 1997; 46: 665-70.
7. Cardiovascular risk factors predict diabetic peripheral neuropathy in Type 1 subjects in Europe. The EURODIAB Prospective Complications Study (PCS) Group. Diabetologia 1999; 42: A50-181.
8. Malik RA. Microalbuminuria-pathophysiology, relevance and treatment. Heart Failure Hypertens 1998; 10: 4-6.
9. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, et al. Effect of the angiotensin-convertingenzyme inhibitor Benzapril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45.
10. Parving H-H, Larsen M, Hommel E, Lund-Andersen H. Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive type 1 diabetic patients with background retinopathy. Diabetologia 1989; 32: 440-4.
11. Chaturvedi N, Sjolie A-K, Stephenson JM, Abrahamian H, Kiepes M, Castellarian A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31.
12. Giannattasio C, Failla M, Piperno A, Grappiolo A, Gamba P, Paleari F, et al. Early impairment of large artery structure and function in Type 1 diabetes mellitus. Diabetologia 1999; 42: 987-94.
13. Enderle M-D, Benda N, Schmuelling R-M, Haering HU, Pfohl M. Preserved endothelial function in IDDM patients, but not in NIDDM patients compared with healthy subjects. Diabetes Care 1998; 21: 271-7.
14. Malik RA, Paniagua O, Shaw L, Austin C, Heagerty AM. Resistance vessel function and structure in normotensive patients with type 1 diabetes. Diabetologia 1999; 42: A75-271.
15. Veves A, Akbari CM, Primavera J, Donaghue VM, Zacharoulis D, Chrzan JS, et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 1998; 47: 457-63.
16. Jude EB, Boulton AJM, Ferguson MWJ, Appleton I. The role of nitric oxide synthase isoforms and arginase in the pathogenesis of diabetic foot ulcers: possible modulatory effects by transforming growth factor beta 1. Diabetologia 1999; 42: 748-57.
17. Hogikyan RV, Wald JJ, Feldman EL, Greene DA, Halter JB, Supiano MA. Acute effects of adrenergic-mediated ischemia on nerve conduction in subjects with type 2 diabetes. Metabolism 1999; 48: 495-500.